proposed in non-small cell lung cancer studies that combining HIF1α inhibitors with programmed cell death protein 1 (PD-1) antibodies enhances T-cell infiltration, suggesting potential dual antitumor effects of targeting HIF1α (44). The gene discussed is HIF1A; the disease is non-small cell lung carcinoma.